Evidence map›Paper›PMID 39930815›Full record

ReviewInternational journal of molecular medicine2025

The role of astrocyte metabolic reprogramming in ischemic stroke (Review).

Weixin Chen, Tangyou Mao, Rui Ma, Yuxuan Xiong, Ran Han, Le Wang

Abstract readReview
In one paragraph

Review in International journal of molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Weixin Chen *Second Clinical Medical College, Beijing University of Chinese Medicine, Beijing 100105, P.R. China.
Tangyou Mao *Gastroenterology Department, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, P.R. China.
Rui MaSecond Clinical Medical College, Beijing University of Chinese Medicine, Beijing 100105, P.R. China.
Yuxuan XiongSecond Clinical Medical College, Beijing University of Chinese Medicine, Beijing 100105, P.R. China.
Ran HanClinical Laboratory Department, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, P.R. China.
Le WangCerebrovascular Disease Department, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ischemic stroke, a leading cause of disability and mortality worldwide, is characterized by the sudden loss of blood flow in specific area of the brain. Intravenous thrombolysis with recombinant tissue plasminogen activator is the only approved pharmacological treatment for acute ischemic stroke; however, the aforementioned treatment has significant clinical limitations, thus there is an urgent need for the development of novel mechanisms and therapeutic strategies for ischemic stroke. Astrocytes, abundant and versatile cells in the central nervous system, offer crucial support to neurons nutritionally, structurally and physically. They also contribute to blood‑brain barrier formation and regulate neuronal extracellular ion concentrations. Accumulated evidence has revealed the involvement of astrocytes in the regulation of host neurotransmitter metabolism, immune response and tissue repair, and different metabolic characteristics of astrocytes can contribute to the process and development of ischemic stroke, suggesting that targeted regulation of astrocyte metabolic reprogramming may contribute to the treatment and prognosis of ischemic stroke. In the present review, the current understanding of the multifaceted mechanisms of astrocyte metabolic reprogramming in ischemic stroke, along with its regulatory factors and pathways, as well as the strategies to promote its polarization balance, which hold promise for astrocyte immunometabolism‑targeted therapies in the treatment of ischemic stroke, were summarized.

Indexed as

AstrocytesBrain IschemiaCellular ReprogrammingIschemic StrokeAnimalsBlood-Brain BarrierHumansMetabolic Reprogrammingastrocyteimmunometabolismischemic strokemetabolic reprogrammingstrategies

Identifiers

PMID39930815
PMCPMC11781528

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.